InterMune (nasdaq)ITMN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: ghmm who wrote (464)	2/3/2009 5:28:19 PM
From: Biomaven	of 508

>>Would it bother you that this is done retrospectively? Well the FDA will look at it skeptically for just that reason. But it's not innately a "cherry-picking" methodology (as would just looking at the data at say 48 weeks). On the one hand it's tempting to say that the reason for the difference between the two trials was that CAP-1 was a sicker population; but based on the data they disclosed today the real difference looks to be the CAP-1 placebo patients slowing their decline after 48 weeks. So maybe it's just a quirk of the numbers and there is no deeper explanation. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next